Breakthrough Biomarker Investigations and Combined Therapeutic Approaches
PARIS - Thursday, September 12th 2013 [ME NewsWire]
June 23-24, 2014 at Hotel Marriott Rive Gauche, Paris, France
(BUSINESS WIRE)-- WIN consortium (www.winconsortium.org) announces an exceptional event entirely dedicated to combining targeted therapies and therapeutic strategies for the treatment of cancer.
“WINning Combinations for Precision Cancer Medicine”]
Breakthrough biomarker investigations and combined therapeutic approaches
Save the date and obtain further information at www.winsymposium.org
"This original theme is for the first time the subject of an international symposium", said Dr. Vladimir Lazar, Chief Operating Officer of WIN consortium. "Join the world’s leaders in precision cancer medicine, Leroy Hood, Richard L. Schilsky, Razelle Kurzrock, Jean-Charles Soria and many others."
"Most patients’ tumors are driven by multiple molecular aberrations that cannot be controlled by a single targeted agent. The challenge is to identify and test smart combinations of targeted agents capable of blocking optimal pathways at the same time" said John Mendelsohn, Chair of the WIN consortium.
Pr. Alexander Eggermont, Vice-Chair of WIN consortium and co-chair of the WIN2014 symposium stated: "Some combinations are currently under investigation. Results of these and additional clinical studies are eagerly awaited as they hold the promise of taking precision cancer medicine to the next level."
The WIN 2014 Symposium will address major developments in precision cancer medicine in sessions featuring the world’s leaders in basic and clinical cancer research, each session being focusing on the rationale for combinations:
Molecular analysis of immune cells and immunotherapy
What can we learn from haemato-oncology?
Learning from fundamental mechanisms in pediatrics and young adults
Combinations of targeted therapies
Tumor cell plasticity and drugable targets
Liquid Biopsies: new technologies, new perspectives
Dr. Vladimir Lazar, +33 1 42 11 40 20